Occurrence of Nephrogenic Systemic Fibrosis with Group II Gadolinium-Based Contrast Agent in a Pediatric Oncology Patient with AKI

被引：0
|
作者：
Hanna, Christian [1 ]
Scheuermann, Amanda [2 ]
Hopp, Amanda M. [2 ]
Young, Kara [2 ]
Dillon, John J. [1 ]
Van Why, Scott K. [2 ]
机构：
[1] Mayo Clin Minnesota, Rochester, MN USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2021年 / 32卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PO2018
引用
收藏
页码：620 / 620
页数：1
相关论文
共 50 条
  • [21] Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency
    Chewning, Rush H.
    Murphy, Kieran J.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2007, 18 (03) : 331 - 333
  • [22] Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis
    Heverhagen, J. T.
    Krombach, G. A.
    Gizewski, E.
    ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN, 2014, 186 (07): : 661 - 669
  • [23] Nephrogenic systemic fibrosis: Recommendations for gadolinium-based contrast use in patients with kidney disease
    Perazella, Mark A.
    Reilly, Robert F.
    SEMINARS IN DIALYSIS, 2008, 21 (02) : 171 - 173
  • [24] MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents Gadolinium Retention and Nephrogenic Systemic Fibrosis
    McDonald, Jennifer S.
    McDonald, Robert J.
    MAGNETIC RESONANCE IMAGING CLINICS OF NORTH AMERICA, 2020, 28 (04) : 497 - +
  • [25] Strong association between the use of gadolinium-based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis
    Jamboti, J.
    INTERNAL MEDICINE JOURNAL, 2007, 37 (07) : 508 - U4
  • [26] Response to "Will dialysis prevent the development of nephrogenic systemic: Fibrosis after gadolinium-based contrast administration?"
    Broome, Dale R.
    Cottrell, Alfred C.
    Kanal, Emanuel
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2007, 189 (04) : W234 - W235
  • [27] Nephrogenic Systemic Fibrosis (NSF) and Gadolinium-Based Contrast Agents (GBCAs). A Statistical Simulation Study
    Michel, Alexander
    Blenk, Tilo
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S84 - S84
  • [28] Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis
    Agarwal, Rajender
    Brunelli, Steven M.
    Williams, Kendal
    Mitchell, Matthew D.
    Feldman, Harold I.
    Umscheid, Craig A.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (03) : 856 - 863
  • [29] Nephrogenic Systemic Fibrosis and Class Labeling of Gadolinium-based Contrast Agents by the Food and Drug Administration
    Yang, Lucie
    Krefting, Ira
    Gorovets, Alex
    Marzella, Louis
    Kaiser, James
    Boucher, Robert
    Rieves, Dwaine
    RADIOLOGY, 2012, 265 (01) : 248 - 253
  • [30] An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis
    Zhang, Bin
    Liang, Long
    Chen, Wenbo
    Liang, Changhong
    Zhang, Shuixing
    PLOS ONE, 2015, 10 (06):
12345